UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 24, 2023

Comera Life Sciences Holdings, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**1-41403**	**87-4706968**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

12 Gill Street
Suite 4650
Woburn, Massachusetts **01801**
(Address of principal executive offices) **(Zip Code)**

Registrant's telephone number, including area code: (617) 871-2101

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CMRA	The Nasdaq Stock Market LLC
Warrants	CMRAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Comera Life Sciences Holdings, Inc. (the "Company") from time to time presents at various industry and other conferences and provides summary business information. A copy of the slide presentation that will be used by representatives of the Company in connection with such presentations (the "Corporate Presentation") is attached to this Current Report on Form 8-K as Exhibit 99.1. The Corporate Presentation is current as of March 24, 2023, and the Company disclaims any obligation to correct or update this material in the future.

The information in the presentation attached as Exhibit 99.1 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Corporate Presentation current as of March 24, 2023
104	Inline XBRL for the cover page of this Current Report on Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 24, 2023

COMERA LIFE SCIENCES HOLDINGS, INC.

By: /s/ Michael Campbell
Name: Michael Campbell
Title: Executive Vice President and Chief Financial Officer

Exhibit 99.1

Corporate Presentation

March 2023

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by forward-looking words such as “may,” “might,” “could,” “will,” “would,” “should,” “expect,” “possible,” “potential,” “anticipate,” “contemplate,” “believe,” “estimate,” “plan,” “predict,” “project,” “intends,” and “continue” or similar words, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: the Company’s ability to maintain the listing of its securities on the Nasdaq Capital Market; the price of the Company’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which the Company plans to operate, variations in performance across competitors, changes in laws and regulations affecting the Company’s business and changes in the capital structure; the Company’s ability to execute on its business plans, forecasts, and other expectations and identify and realize additional opportunities; the risk of economic downturns and the possibility of rapid change in the highly competitive industry in which the Company operates; the risk that the Company and its current and future collaborators are unable to successfully develop and commercialize the Company’s products or services, or experience significant delays in doing so; the risk that we will be unable to continue to attract and retain third-party collaborators, including collaboration partners and licensors; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that the Company is unable to secure or protect its intellectual property; the risk that the Company is unable to secure regulatory approval for its product candidates; the effect of any resurgence of the COVID-19 pandemic or other public health emergencies on the Company’s business; general economic conditions; and other risks and uncertainties described in the Company’s Annual Report on Form 10-K filed with the SEC on March 17, 2023 under “Risk Factors” and in other filings that have been made or will be made with the SEC.

Accordingly, nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved, and any forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Experienced and Accomplished Management Team

Comera LIFE SCIENCES

Jeffrey S. Hackman
Chairman and Chief Executive Officer

EUSAPharma · novelion THERAPEUTICS · Baxalta · sigma-tau PHARMACEUTICALS, INC. · Shire · MedImmune

Neal I. Muni, MD, MSPH
Chief Operating Officer

azurity pharmaceuticals · CUTISPHARMA · BRIGHAM AND WOMEN'S HOSPITAL · HARVARD MEDICAL SCHOOL · LEERINK · WYSS INSTITUTE · SUNOVION · FDA

Robert Mahoney, Ph.D.
Chief Scientific Officer

SOANE ENERGY · CROP ENHANCEMENT · NALCO Water An Ecolab Company · Polymer Ventures

Michael Campbell
Chief Financial Officer

Boston Scientific · Ortho Clinical Diagnostics · MONOMOY ADVISORS · EY

Janice Marie McCourt
Chief Business Officer

LYVGEN · Abbott · agenus · TAR · Takeda · EDGEMONT PHARMACEUTICALS · PRAECIS · Heat Biologics · UnitedHealth Group

Successful track record of drug development and life sciences operating expertise

Comera Life Sciences Investment Highlights

Validating Partnerships 	• 3 active R&D partnerships: opportunity to negotiate potentially significant upfront/milestone payments and product royalties • Broadly applicable technology, multiple ongoing discussions for additional R&D partnerships
Evolutionary Technology 	• Technology enables subcutaneous (SQ) delivery of IV biologics • Proprietary SQore technology protected by robust patent portfolio • $30+ million invested to date over the past 10 years • Offers potential for product life-cycle management and competitive advantages
Significant Market Opportunity 	• Opportunity within a variety of existing multi-billion dollar commercial markets • Potential benefit to patient, provider, and healthcare system • Demonstrated ability to substantially enhance potential for deeper market penetration
Capital Efficient Business Model 	• Partners assume responsibility for downstream clinical development • Lower risk clinical development strategy • Minimal incremental spend to near-term value inflection points

Comera Life Sciences Value Development Overview

Comera LIFE SCIENCES

Partnership Pipeline

Partner	*Partnering Stage*			
	Engagement	Evaluation Agreement	Licensing	Milestones/ Royalties
REGENERON	→	→		
Undisclosed Top 10 Pharma Company	→	→		
INTAS	→	→		
	~6-12 months	*~6-18 months*	*~3-18 months*	*~12+ months*

Clinical Development Pipeline

Asset Name	Formulation	Pre-Clinical	Clinical Trials	Approval
CLS-001	→	→		

Significant Inbound Interest as Well as BD Outreach Efforts Drive Partnerships

Comera LIFE SCIENCES

Large Potential Target Universe (Pharmas, Biotechs, CDMOs)

Target Engagement

"It would take us over ten years to build a working formulation department, so we prefer to work with Comera to jump start this initiative."

- Chief Strategy Officer, Major Biosimilars Company

~6-12 months

Proposals

~1-3 months

Research Collaborations

"We love the work at Comera to solve formulation issues that we have not been able to solve ourselves."

- Head of BD, Large Biotech

Current Partnerships

Top 10 Pharma Company

REGENERON

INTAS

Self-Administered, SQ Biologic Dosing has Multiple Potential Benefits over IV Infusion



IV SQ

For Patients

Better Patient Outcomes

- ✓ Potential for improved compliance
- ✓ Significantly reduced administration time
- ✓ Increased convenience/quality of life
- ✓ Strong physician preference (over 70% prefer SQ to IV biologic, if available)*

For Payers

Reduced Healthcare Costs

- ✓ IV infusion centers and staffing not required
- ✓ Potential for improved outcomes
- ✓ Decreased healthcare professional time spent on disease management

For Pharma Partners

Increased Revenue

- ✓ Extend franchise life & patent protections
- ✓ Increased market share
- ✓ Rescue efficacious drugs terminated due to formulation/administration issues

Potential Advantages of SQ over IV

*Source: Ipsos market study and Comera physician interviews, December 2021; base: Total HCPs; n=50 + 5 IDIs with high-prescribing physicians

Formulating SQ Biologics is Technically Challenging, Without Much Innovation by Pharma in this Space

Comera LIFE SCIENCES

High Viscosity a Significant Hurdle to Formulating SQ Biologics



High Viscosity

Results from high protein concentration and limits IV to SQ conversion

Low Viscosity

SQore technology enables IV to SQ conversion by reducing viscosity

Lack of innovation highlighted by FDA Novel Excipient Review Pilot Program

First proposals accepted December 2021

FDA U.S. FOOD & DRUG ADMINISTRATION

Novel Excipient Review Pilot Program

The Center for Drug Evaluation and Research (CDER) has launched the voluntary Novel Excipient Review Pilot Program (Pilot Program), which is intended to allow excipient manufacturers to obtain FDA review of certain novel excipients prior to their use in drug formulations. This Pilot Program will foster development of excipients that may be useful in scenarios in which excipient manufacturers and drug developers have cited difficulty in using existing excipients.

Pharma Has Not Brought Innovative New Technology to Solve Problem

Historically Reliant on Old, Off-the-Shelf Excipient Technology

SQ Value Proposition Validated by Market Conversions

- **Global biologics market ~$383B in 2022, growing at an 8.8% CAGR through 2032[1]**
- **Majority of biologics are IV infusions**
- **Significant industry interest in converting IV biologics to SQ**



SQ Market Penetration After IV Conversion

Case Study of Selected Biologic Analogues



Source: Symphony; FDA; Biosimilar Development; L.E.K. interviews, research and analysis; https://www.fiercepharma.com/pharma/jjs-switch-iv-subcutaneous-darzalex-85-complete-us#:~:text=Johnson%20%26%20Johnson's%20attempt%20to%20switch,formulation%20of%20the%20cancer%20treatment.

**Herceptin Hylecta utilizes different technology for SQ delivery (Halozyme ENHANZE), which still requires HCP administration in institutional setting, likely dampening rate of conversion*

Our Solution: The SQore™ Viscosity Reduction Platform

$30M invested over 10 years to build and validate SQore technology

Comera LIFE SCIENCES



What is SQore?

SQore is the integration of advanced computational modeling, a robust library of carefully selected excipients, and protein formulation engineering by an expert team of scientists

- **SQore platform predictions validated by testing on 20 different mAbs**
- **Lead, caffeine-based SQore excipient evaluated in four pre-clinical studies**
  - Validated safety
  - Validated pharmacokinetics of antibody absorption
- **Robust IP portfolio, with 13 patents issued and >35 patents pending**
  - 3 patent families including viscosity reduction, stabilization, process
  - Multiple key geographies
  - Coverage up to mid-2040s

SQore™ Offers Advantages vs. Other SQ Formulation Approaches

	IP-Protected and Previous Human Use	Does Not Alter Antibody Properties	Can Be Taken At Home by Patient
Comera LIFE SCIENCES	✓	✓	✓
elektrofi	✓		✓
Halozyme	✓	✓	
Lindy Biosciences	✓		✓
Arecor		✓	✓
ARSIA / EAGLE PHARMACEUTICALS		✓	✓
integritybio		✓	✓
ALTEOGEN Inc.	✓	✓	

SQore™: Validated by Scientific Peer-Review

Caffeine-based lead SQore excipient proven in externally validated, rigorous scientific evaluation to achieve parameters that we believe demonstrate a viable SQ formulation

- Lead SQore excipient, caffeine, used to show SQ formulation proof of concept for two leading mAbs

Remicade® INFLIXIMAB

YERVOY® (ipilimumab)

- Significant viscosity reduction
- No effect on mAb stability
- No loss of biological activity

Source: "Caffeine as a viscosity reducer for highly concentrated monoclonal antibody solutions", *Journal of Pharmaceutical Sciences*, 110 (2021) 3594−3604, https://doi.org/10.1016/j.xphs.2021.06.030

SQore™ Platform Optimized to Lower Viscosity for Several Biologics

Comera LIFE SCIENCES



Remicade® INFLIXIMAB

Infliximab formulated in a 20 mM phosphate-acetate buffer at pH 6.0 (control) and in the presence of 75 mM caffeine, 100 mM ArgHCl, or 100 mM NaCl



YERVOY® (ipilimumab)

Ipilimumab formulated in Yervoy commercial formulation vehicle (Comm.) and PBS with or without 75 mM caffeine

Source: "Caffeine as a viscosity reducer for highly concentrated monoclonal antibody solutions" Journal of Pharmaceutical Sciences 110 (2021) 3594–3604 https://doi.org/10.1016/j.xphs.2021.06.030

Selective Focus on High-Value Partnerships With Potential Near-Term Milestone Value

200+ potential therapeutic antibody program candidates for research collaboration



Selected research collaboration

Partnership Value Generated Through Multiple Stages

Evaluation agreements are the first stage to long-term royalty streams

Evaluation Agreements (~6-18 months)

Revenue generating research collaboration to assess feasibility **(~$350K-1M+)**

License Option Exercise (~3-18 months)

Potential **$multi-million** upfront payment to license SQore technology **(~$10-100M+)**[1]

Milestones/Royalties (12+ months)

Potential **$multi-million** payments upon achievement of key development milestones

Potential **single to mid-teen %** royalty on product sales



[1]*Based on BioPharma transactions included in the J.P Morgan Biopharma Therapeutics Licensing Deals and Venture April 2022 report; DealForma.com database. Data through 4/7/2022*

Multiple SQ Opportunities for Internal Pipeline

Several opportunities appear to be attractive for internal development into SQ formulations, representing low capital intensity, lower risk opportunities targeting large markets.

CLS-001 (SQ Vedolizumab): Initial Product Candidate

CLS-001 is a potential multibillion-dollar opportunity to bring differentiated value to improve the lives of patients with a self-administered SQ formulation having reduced dosing frequency

Program	SQ formulation of vedolizumab
Therapeutic Area	IBD *Ulcerative colitis and Crohn's disease*
Development Status	Formulation development
Competition	No SQ currently in US *Estimated SQ Entyvio approval 2024*
Differentiation	Once monthly SQ dosing vs. every 2 weeks
Peak Annual Sales Potential	~$2B

Blockbuster product - large conversion opportunity

Entyvio vedolizumab

WW Sales (2021): **$4B**

Estimated Peak (2026+): **$7.5-9.0B**

Source: : L.E.K market research and analysis, January 2022; EvaluatePharma; Biosimilardevelopment.com; Parrish (2020); Company website; Cowen (09.2021); SVB Leerink (10.2021); H.C. Wainwright (10.2021); Jefferies (07.2021); https://www.takeda.com/4ada11/siteassets/system/investors/report/quarterlyannouncements/fy2022/qr2022_q2_p01_en.pdf

Comera Life Sciences Investment Highlights

Validating Partnerships	• 3 active R&D partnerships: opportunity to negotiate potentially significant upfront/milestone payments and product royalties • Broadly applicable technology, multiple ongoing discussions for additional R&D partnerships
Evolutionary Technology	• Technology enables subcutaneous delivery of IV biologics • Proprietary SQore technology protected by robust patent portfolio • $30+ Million invested to date over the past 10 years • Offers potential for product life-cycle management and competitive advantages
Significant Market Opportunity	• Opportunity within a variety of existing multi-billion dollar commercial markets • Potential benefit to patient, provider, and healthcare system • Demonstrated ability to substantially enhance potential for deeper market penetration
Capital Efficient Business Model	• Partners assume responsibility for downstream clinical development • Lower risk clinical development strategy • Minimal incremental spend to near-term value inflection points

Thank you!

Investor Contact
John Woolford
ICR Westwicke
John.Woolford@westwicke.com

Press Contact
Jon Yu
ICR Westwicke
comerapr@westwicke.com

12 Gill Street, Suite 4650
Woburn, MA 01801, USA
comeralifesciences.com